[1]
Chaichan P, Mercier A, Galal L, Mahittikorn A, Ariey F, Morand S, Boumédiène F, Udonsom R, Hamidovic A, Murat JB, Sukthana Y, Dardé ML. Geographical distribution of Toxoplasma gondii genotypes in Asia: A link with neighboring continents. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2017 Sep:53():227-238. doi: 10.1016/j.meegid.2017.06.002. Epub 2017 Jun 3
[PubMed PMID: 28583867]
[2]
Maenz M, Schlüter D, Liesenfeld O, Schares G, Gross U, Pleyer U. Ocular toxoplasmosis past, present and new aspects of an old disease. Progress in retinal and eye research. 2014 Mar:39():77-106. doi: 10.1016/j.preteyeres.2013.12.005. Epub 2014 Jan 9
[PubMed PMID: 24412517]
[3]
Kijlstra A, Petersen E. Epidemiology, pathophysiology, and the future of ocular toxoplasmosis. Ocular immunology and inflammation. 2014 Apr:22(2):138-47. doi: 10.3109/09273948.2013.823214. Epub 2013 Oct 16
[PubMed PMID: 24131274]
[4]
Filloy A, Garcia-Garcia O, Fernández-Lorente L. Chorioretinitis as the first sign of acquired toxoplasmosis transmitted from donor following kidney transplantation: case report and review of the literature. Ocular immunology and inflammation. 2013:21(1):34-5. doi: 10.3109/09273948.2012.726390. Epub
[PubMed PMID: 23323579]
Level 3 (low-level) evidence
[5]
Mikhail MA, Varikkara M. The absence of vitreous inflammation: one more challenge in diagnosing toxoplasma papillitis. BMJ case reports. 2013 Apr 9:2013():. doi: 10.1136/bcr-2013-008962. Epub 2013 Apr 9
[PubMed PMID: 23576658]
Level 3 (low-level) evidence
[6]
Aleixo AL, Curi AL, Benchimol EI, Amendoeira MR. Toxoplasmic Retinochoroiditis: Clinical Characteristics and Visual Outcome in a Prospective Study. PLoS neglected tropical diseases. 2016 May:10(5):e0004685. doi: 10.1371/journal.pntd.0004685. Epub 2016 May 2
[PubMed PMID: 27136081]
[7]
Azevedo MH, Moura GL, Camilo EN, Muccioli C, Arantes TE. Visual function and macular architecture in patients with inactive zone 2 and 3 toxoplasmic retinochoroiditis. Arquivos brasileiros de oftalmologia. 2015 Sep-Oct:78(5):273-7. doi: 10.5935/0004-2749.20150073. Epub
[PubMed PMID: 26466223]
[8]
Kato K. How does Toxoplama gondii invade host cells? The Journal of veterinary medical science. 2018 Nov 23:80(11):1702-1706. doi: 10.1292/jvms.18-0344. Epub 2018 Oct 4
[PubMed PMID: 30282883]
[9]
Khan K, Khan W. Congenital toxoplasmosis: An overview of the neurological and ocular manifestations. Parasitology international. 2018 Dec:67(6):715-721. doi: 10.1016/j.parint.2018.07.004. Epub 2018 Jul 21
[PubMed PMID: 30041005]
Level 3 (low-level) evidence
[10]
Clough B, Frickel EM. The Toxoplasma Parasitophorous Vacuole: An Evolving Host-Parasite Frontier. Trends in parasitology. 2017 Jun:33(6):473-488. doi: 10.1016/j.pt.2017.02.007. Epub 2017 Mar 19
[PubMed PMID: 28330745]
[11]
White MW, Suvorova ES. Apicomplexa Cell Cycles: Something Old, Borrowed, Lost, and New. Trends in parasitology. 2018 Sep:34(9):759-771. doi: 10.1016/j.pt.2018.07.006. Epub 2018 Aug 2
[PubMed PMID: 30078701]
[12]
Galal L, Schares G, Stragier C, Vignoles P, Brouat C, Cuny T, Dubois C, Rohart T, Glodas C, Dardé ML, Kane M, Niang Y, Diallo M, Sow A, Aubert D, Hamidović A, Ajzenberg D, Mercier A. Diversity of Toxoplasma gondii strains shaped by commensal communities of small mammals. International journal for parasitology. 2019 Mar:49(3-4):267-275. doi: 10.1016/j.ijpara.2018.11.004. Epub 2018 Dec 20
[PubMed PMID: 30578812]
[13]
Rostami A, Riahi SM, Fakhri Y, Saber V, Hanifehpour H, Valizadeh S, Gholizadeh M, Pouya RH, Gamble HR. The global seroprevalence of Toxoplasma gondii among wild boars: A systematic review and meta-analysis. Veterinary parasitology. 2017 Sep 15:244():12-20. doi: 10.1016/j.vetpar.2017.07.013. Epub 2017 Jul 21
[PubMed PMID: 28917302]
Level 1 (high-level) evidence
[14]
Holland GN. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. American journal of ophthalmology. 2004 Jan:137(1):1-17
[PubMed PMID: 14700638]
[15]
Jones JL, Kruszon-Moran D, Elder S, Rivera HN, Press C, Montoya JG, McQuillan GM. Toxoplasma gondii Infection in the United States, 2011-2014. The American journal of tropical medicine and hygiene. 2018 Feb:98(2):551-557. doi: 10.4269/ajtmh.17-0677. Epub 2017 Dec 14
[PubMed PMID: 29260660]
[16]
El Bissati K, Levigne P, Lykins J, Adlaoui EB, Barkat A, Berraho A, Laboudi M, El Mansouri B, Ibrahimi A, Rhajaoui M, Quinn F, Murugesan M, Seghrouchni F, Gómez-Marín JE, Peyron F, McLeod R. Global initiative for congenital toxoplasmosis: an observational and international comparative clinical analysis. Emerging microbes & infections. 2018 Sep 27:7(1):165. doi: 10.1038/s41426-018-0164-4. Epub 2018 Sep 27
[PubMed PMID: 30262847]
Level 2 (mid-level) evidence
[17]
Constantin F, Denislam D. [Congenital toxoplasmosis with ocular involvment--case report]. Oftalmologia (Bucharest, Romania : 1990). 2014:58(1):42-7
[PubMed PMID: 25145122]
Level 3 (low-level) evidence
[18]
Kharel Sitaula R, Joshi SN, Sah R, Khadka S, Khatri Kc A, Pokharel BM. Toxoplasma gondii bradyzoites and tachyzoites isolation from vitreous of atypical necrotizing retinitis. Journal of ophthalmic inflammation and infection. 2018 Jun 15:8(1):8. doi: 10.1186/s12348-018-0151-x. Epub 2018 Jun 15
[PubMed PMID: 29904801]
[19]
Deigendesch N, Costa Nunez J, Stenzel W. Parasitic and fungal infections. Handbook of clinical neurology. 2017:145():245-262. doi: 10.1016/B978-0-12-802395-2.00018-3. Epub
[PubMed PMID: 28987173]
[20]
Crosson JN, Laird PW, Grossniklaus HE, Hendrick AM. Toxoplasma chorioretinitis diagnosed by histopathology in a patient with AIDS. Retinal cases & brief reports. 2015 Spring:9(2):162-3. doi: 10.1097/ICB.0000000000000126. Epub
[PubMed PMID: 25621872]
Level 3 (low-level) evidence
[22]
Marra CM. Central nervous system infection with Toxoplasma gondii. Handbook of clinical neurology. 2018:152():117-122. doi: 10.1016/B978-0-444-63849-6.00009-8. Epub
[PubMed PMID: 29604970]
[23]
Gologorsky D. Eponymous Dishonor: Kyrieleis Plaques. Retina (Philadelphia, Pa.). 2018 Jul:38(7):1261-1262. doi: 10.1097/IAE.0000000000002235. Epub
[PubMed PMID: 29923885]
[24]
Zhioua Braham I, Boukari M, Ammous I, Mili Boussen I, Errais K, Zhioua R. Bilateral congenital macular coloboma: Swept-source optical coherence tomography findings. La Tunisie medicale. 2018 Aug-Sep:96(8-9):524-527
[PubMed PMID: 30430533]
[26]
Sauer A, Villard O, Bourcier T, Speeg-Schatz C, Candolfi E. [Ocular toxoplasmosis: from pathophysiology to microbiological diagnosis]. Journal francais d'ophtalmologie. 2013 Jan:36(1):76-81. doi: 10.1016/j.jfo.2012.05.004. Epub 2012 Dec 6
[PubMed PMID: 23219508]
[27]
Saadatnia G, Golkar M. A review on human toxoplasmosis. Scandinavian journal of infectious diseases. 2012 Nov:44(11):805-14. doi: 10.3109/00365548.2012.693197. Epub 2012 Jul 25
[PubMed PMID: 22831461]
[28]
Bolduc P, Roder N, Colgate E, Cheeseman SH. Care of Patients With HIV Infection: Medical Complications and Comorbidities. FP essentials. 2016 Apr:443():16-22
[PubMed PMID: 27092563]
[29]
Hegde S, Relhan N, Pathengay A, Bawdekar A, Choudhury H, Jindal A, Flynn HW Jr. Coexisting choroidal neovascularization and active retinochoroiditis-an uncommon presentation of ocular toxoplasmosis. Journal of ophthalmic inflammation and infection. 2015:5():22. doi: 10.1186/s12348-015-0051-2. Epub 2015 Jul 12
[PubMed PMID: 26185543]
[30]
Errera MH, Chahed S, Man H, Garin YJ, Bergmann JF, Gaudric A, Massin P. [Severe disseminated toxoplasmosis with atypical chorioretinitis. A case of primary infection]. Journal francais d'ophtalmologie. 2009 May:32(5):348.e1-5. doi: 10.1016/j.jfo.2009.02.004. Epub 2009 May 17
[PubMed PMID: 19769872]
Level 3 (low-level) evidence
[31]
Imai H, Azumi A, Nagai T, Yamamoto H, Negi A, Ohbayashi C. A case of ocular toxoplasmosis: direct proof of the protozoan infection by retinal biopsy. Retinal cases & brief reports. 2008 Winter:2(1):76-9. doi: 10.1097/01.iae.0000249391.22195.bd. Epub
[PubMed PMID: 25389626]
Level 3 (low-level) evidence
[32]
Zhang Y, Lin X, Lu F. Current treatment of ocular toxoplasmosis in immunocompetent patients: a network meta-analysis. Acta tropica. 2018 Sep:185():52-62. doi: 10.1016/j.actatropica.2018.04.026. Epub 2018 Apr 25
[PubMed PMID: 29704469]
Level 1 (high-level) evidence
[33]
Kim SJ, Scott IU, Brown GC, Brown MM, Ho AC, Ip MS, Recchia FM. Interventions for toxoplasma retinochoroiditis: a report by the American Academy of Ophthalmology. Ophthalmology. 2013 Feb:120(2):371-8. doi: 10.1016/j.ophtha.2012.07.061. Epub 2012 Oct 11
[PubMed PMID: 23062648]
[34]
Stanford MR, See SE, Jones LV, Gilbert RE. Antibiotics for toxoplasmic retinochoroiditis: an evidence-based systematic review. Ophthalmology. 2003 May:110(5):926-31; quiz 931-2
[PubMed PMID: 12750091]
Level 1 (high-level) evidence
[35]
Ahmed A, Sudharshan S, Gopal S, Majumder PD, Biswas J. Toxoplasma retinitis following intravitreal injection of triamcinolone acetonide: A case report and review of literature. Indian journal of ophthalmology. 2018 Aug:66(8):1205-1208. doi: 10.4103/ijo.IJO_142_18. Epub
[PubMed PMID: 30038184]
Level 3 (low-level) evidence
[36]
Harrell M, Carvounis PE. Current treatment of toxoplasma retinochoroiditis: an evidence-based review. Journal of ophthalmology. 2014:2014():273506. doi: 10.1155/2014/273506. Epub 2014 Aug 13
[PubMed PMID: 25197557]
[37]
Katlama C, Mouthon B, Gourdon D, Lapierre D, Rousseau F. Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group. AIDS (London, England). 1996 Sep:10(10):1107-12
[PubMed PMID: 8874627]
[38]
Felix JP, Lira RP, Zacchia RS, Toribio JM, Nascimento MA, Arieta CE. Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of Toxoplasma gondii retinochoroiditis: randomized controlled clinical trial. American journal of ophthalmology. 2014 Apr:157(4):762-766.e1. doi: 10.1016/j.ajo.2013.12.022. Epub 2014 Jan 3
[PubMed PMID: 24388839]
Level 1 (high-level) evidence
[39]
Ganesh SK, Ali BS, Madhavan HN. Infectious chorioretinitis in an immunocompetent patient: A diagnostic dilemma. Indian journal of ophthalmology. 2017 Oct:65(10):1043-1046. doi: 10.4103/ijo.IJO_190_17. Epub
[PubMed PMID: 29044084]
[40]
Matet A, Paris L, Fardeau C, Terrada C, Champion E, Fekkar A, Cassoux N, Touitou V, LeHoang P, Bodaghi B. Clinical and Biological Factors Associated With Recurrences of Severe Toxoplasmic Retinochoroiditis Confirmed by Aqueous Humor Analysis. American journal of ophthalmology. 2019 Mar:199():82-93. doi: 10.1016/j.ajo.2018.11.013. Epub 2018 Nov 28
[PubMed PMID: 30502335]
[41]
Torgerson PR, Devleesschauwer B, Praet N, Speybroeck N, Willingham AL, Kasuga F, Rokni MB, Zhou XN, Fèvre EM, Sripa B, Gargouri N, Fürst T, Budke CM, Carabin H, Kirk MD, Angulo FJ, Havelaar A, de Silva N. World Health Organization Estimates of the Global and Regional Disease Burden of 11 Foodborne Parasitic Diseases, 2010: A Data Synthesis. PLoS medicine. 2015 Dec:12(12):e1001920. doi: 10.1371/journal.pmed.1001920. Epub 2015 Dec 3
[PubMed PMID: 26633705]
[42]
Yan C, Liang LJ, Zheng KY, Zhu XQ. Impact of environmental factors on the emergence, transmission and distribution of Toxoplasma gondii. Parasites & vectors. 2016 Mar 10:9():137. doi: 10.1186/s13071-016-1432-6. Epub 2016 Mar 10
[PubMed PMID: 26965989]